Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 6:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 74 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Darunavir/Ritonavir Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants

NCT02159352
View directory record Official record
Conditions
Hepatitis C
Interventions
Daclatasvir, Darunavir, Ritonavir, Lopinavir/Ritonavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 49 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2015 · Synced Sep 30, 2026, 6:49 PM EDT
Completed Phase 1Phase 2 Interventional

Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children

NCT00260078
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir, Darunavir, Efavirenz, Nevirapine, Ritonavir, Tenofovir disoproxil fumarate, Pharmacokinetic Study
Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 17 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
21
States / cities
Alhambra, California • La Jolla, California • Long Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Sep 30, 2026, 6:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications

NCT00877591
View directory record Official record
Conditions
Opioid Dependency, HIV Infections
Interventions
Fosamprenavir/Ritonavir, Darunavir/Ritonavir, Rifampin, Rifabutin, Buprenorphine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Sep 30, 2026, 6:49 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

NCT02603107
View directory record Official record
Conditions
HIV-1 Infection
Interventions
RTV, ATV, DRV, COBI, ATV/co, DRV/co, FTC/TDF, ABC/3TC, B/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
63
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 49 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Sep 30, 2026, 6:49 PM EDT
Approved For Marketing No phase listed Expanded access

TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.

NCT00245739
View directory record Official record
Conditions
HIV Infections
Interventions
TMC-114
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
202
States / cities
Anniston, Alabama • Birmingham, Alabama • Mesa, Arizona + 199 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2014 · Synced Sep 30, 2026, 6:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir

NCT00867152
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Darunavir, Etravirine, Ritonavir, Lopinavir/ritonavir, GSK1349572
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Sep 30, 2026, 6:49 PM EDT
Completed Phase 3 Interventional

TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients

NCT00110877
View directory record Official record
Conditions
HIV Infection
Interventions
LPV/rtv, TMC114/rtv
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
39
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2015 · Synced Sep 30, 2026, 6:49 PM EDT
Completed Phase 4 Interventional Results available

CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery

NCT00925756
View directory record Official record
Conditions
HIV Infections
Interventions
Maraviroc
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
3
States / cities
Los Angeles, California • San Diego, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Sep 30, 2026, 6:49 PM EDT
Completed Phase 2 Interventional Results available

Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults

NCT00830804
View directory record Official record
Conditions
HIV-1 Infections
Interventions
Raltegravir, Darunavir/Ritonavir
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
22
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Sep 30, 2026, 6:49 PM EDT
Completed Phase 3 Interventional Results available

A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women

NCT00855335
View directory record Official record
Conditions
HIV, HIV Infections, Pregnancy
Interventions
Darunavir, Ritonavir, Etravirine, Rilpivirine, Darunavir/Cobicistat (FDC)
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
16
States / cities
Daytona Beach, Florida • Jacksonville, Florida • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Sep 30, 2026, 6:49 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)

NCT00524368
View directory record Official record
Conditions
Human Immunodeficiency Virus - Type 1
Interventions
Darunavir (DRV), Ritonavir (rtv)
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
30
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Sep 30, 2026, 6:49 PM EDT
Completed Phase 1 Interventional

Drug Interaction Study Between Inhaled Beclomethasone and Protease Inhibitors in Healthy Volunteers

NCT00936793
View directory record Official record
Conditions
HIV, Asthma
Interventions
Darunavir, Ritonavir, Beclomethasone Dipropionate HFA
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 60 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Sep 30, 2026, 6:49 PM EDT
Completed Phase 4 Interventional Results available

Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r

NCT00756730
View directory record Official record
Conditions
HIV Infections
Interventions
ATV/r, DRV/r
Drug
Lead sponsor
Community Research Initiative of New England
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Sep 30, 2026, 6:49 PM EDT
Completed Phase 2 Interventional

TMC114-C202: A Study of Safety, Efficacy, and Tolerability of TMC114 and Low Dose Ritonavir in HIV-1 Infected Patients

NCT00071097
View directory record Official record
Conditions
HIV Infections
Interventions
TMC114/rtv
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years to 99 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2016 · Synced Sep 30, 2026, 6:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 PK and CYP450 Probe Drugs

NCT00920088
View directory record Official record
Conditions
Healthy Subjects, Infection, Human Immunodeficiency Virus
Interventions
darunavir/ritonavir, lopinavir/ritonavir, Midazolam, Dextromethorphan, Flurbiprofen, GSK2248761
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2010 · Synced Sep 30, 2026, 6:49 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin

NCT00630734
View directory record Official record
Conditions
HIV Infections, Hyperlipidemia
Interventions
Pravastatin, Darunavir, Ritonavir, Washout
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Sep 30, 2026, 6:49 PM EDT
Completed Phase 4 Interventional

Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients

NCT00677300
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir, Darunavir, Ritonavir, Tenofovir/Emtricitabine
Drug
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Sep 30, 2026, 6:49 PM EDT
Completed Phase 2 Interventional Results available

TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents

NCT00665847
View directory record Official record
Conditions
HIV-1
Interventions
Etravirine (TMC125), Optimized background regimen (OBR)
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
6 Years to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
13
States / cities
Mobile, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Sep 30, 2026, 6:49 PM EDT
Terminated No phase listed Observational Results available

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

NCT04518228
View directory record Official record
Conditions
HIV, Tuberculosis
Interventions
Bictegravir (BIC), Tenofovir alafenamide (TAF), Long-acting injectable formulation of cabotegravir (CAB LA), Dolutegravir (DTG), Atazanavir/ritonavir (ATV/r), Darunavir/ritonavir (DRV/r), Lopinavir/ritonavir (LPV/r), Cobicistat, Ritonavir, First-Line TB Treatment, Second-Line TB Treatment, Doravirine (DOR)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 30, 2026, 6:49 PM EDT
Completed Phase 3 Interventional Results available

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

NCT01363011
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
E/C/F/TDF, COBI, ATV, DRV, NRTI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Sep 30, 2026, 6:49 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

NCT01252940
View directory record Official record
Conditions
HIV-1 Infection
Interventions
FTC/RPV/TDF, PI, RTV, NRTIs
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
66
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2015 · Synced Sep 30, 2026, 6:49 PM EDT
Completed Phase 2 Interventional

An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.

NCT00081588
View directory record Official record
Conditions
HIV Infection
Interventions
TMC114
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
26
States / cities
Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2014 · Synced Sep 30, 2026, 6:49 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART

NCT01869634
View directory record Official record
Conditions
Human Immunodeficiency Virus Infection
Interventions
darunavir with ritonavir and fixed-dose viread+emtricitabine daily
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
21 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Sep 30, 2026, 6:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Drug Interaction Study With Protease Inhibitors

NCT00774735
View directory record Official record
Conditions
Healthy Subjects, Infection, Human Immunodeficiency Virus
Interventions
GSK1349572
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2010 · Synced Sep 30, 2026, 6:49 PM EDT